Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting

Laurie H. Sehn, Jane Donaldson, Allison Filewich, Catherine Fitzgerald, Karamjit K. Gill, Nancy Runzer, Barb Searle, Sheila Souliere, John J. Spinelli, Judy Sutherland, Joseph M. Connors

Blood (2007) 109 (10): 4171–4173.

https://doi.org/10.1182/blood-2006-11-059469

Published: 2007

Journal Articles

Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.

Laurie H. Sehn, MD, MPH, Mukesh Chhanabhai, MD, Karamjit Gill, MD, Paul Hoskins, MD, Richard Klasa, MD, Kerry J. Savage, MD, Tamara Shenkier, MD, Judy Sutherland, MD, Randy D. Gascoyne, MD, Joseph M. Connors, MD

Blood (2006) 108 (11): 2739.

https://doi.org/10.1182/blood.V108.11.2739.2739

Published: 2006

Journal Articles

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Judy Sutherland, Randy D. Gascoyne, Joseph M. Connors

Blood (2006) 109 (5): 1857–1861.

https://doi.org/10.1182/blood-2006-08-038257

Published: 2006

Journal Articles

Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).

Laurie H. Sehn, MD, MPH, Mukesh Chhanabhai, MD, Catherine Fitzgerald, MD, Karamjit Gill, MD, Paul Hoskins, MD, Richard Klasa, MD, Kerry Savage, MD, Tamara Shenkier, MD, Judy Sutherland, MD, Kenneth Wilson, MD, Randy D. Gascoyne, MD, Joseph M. Connors, MD

Blood (2005) 106 (11): 492.

https://doi.org/10.1182/blood.V106.11.492.492

Published: 2005

Journal Articles

Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.

Laurie H. Sehn, MD, MPH, Jane Donaldson, Allison Filewich, RN, Catherine Fitzgerald, MD, Karamjit K. Gill, MD, Nancy Runzer, RN, Barb Searle, RN, Sheila Souliere, MD, John J. Spinelli, PhD, Judy Sutherland, MD, Joseph M. Connors, MD

Blood (2004) 104 (11): 1407.

https://doi.org/10.1182/blood.V104.11.1407.1407

Published: 2004

NARROW

Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting

Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).

Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.

Email alerts

ASH Publications

American Society of Hematology

Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting

Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).

Rapid Infusion Rituximab in Combination with Steroid Containing Chemotherapy Can Be Given Safely and Substantially Reduces Resource Utilization.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only